Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Gains from Investment Securities (2018 - 2025)

Inmune Bio's Gains from Investment Securities history spans 8 years, with the latest figure at $7.3 million for Q2 2025.

  • For Q2 2025, Gains from Investment Securities rose 15.73% year-over-year to $7.3 million; the TTM value through Jun 2025 reached $7.3 million, up 15.73%, while the annual FY2024 figure was $7.2 million, 69049.53% up from the prior year.
  • Gains from Investment Securities for Q2 2025 was $7.3 million at Inmune Bio, roughly flat from $7.3 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $7.3 million in Q1 2025 and bottomed at $5417.0 in Q2 2023.
  • The 5-year median for Gains from Investment Securities is $4.8 million (2022), against an average of $3.7 million.
  • The largest annual shift saw Gains from Investment Securities plummeted 99.89% in 2023 before it soared 116049.29% in 2024.
  • A 5-year view of Gains from Investment Securities shows it stood at $4.1 million in 2021, then grew by 18.17% to $4.8 million in 2022, then plummeted by 99.78% to $10417.0 in 2023, then surged by 69049.53% to $7.2 million in 2024, then rose by 1.08% to $7.3 million in 2025.
  • Per Business Quant, the three most recent readings for INMB's Gains from Investment Securities are $7.3 million (Q2 2025), $7.3 million (Q1 2025), and $7.2 million (Q4 2024).